How effective are current drugs for crohn’s disease?: A meta-analysis

Journal of Clinical Gastroenterology

Volumn 14, Issue 3, 1992, Pages 211-215

  Salomon, Peter ^a   Kornbluth, Asher ^a   Aisenberg, James ^a   Janowitz, Henry D ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

Controlled trials; Crohn s disease; Drug therapy; Inflammatory bowel disease; Meta analysis; Placebo

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; STATISTICAL ANALYSIS;

CROHN DISEASE; HUMAN; META-ANALYSIS; REMISSION INDUCTION;

EID: 0026773739     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/00004836-199204000-00006     Document Type: Article

References (19)

1. Archambault A, Feegan B, Fedorak R, et al. The Canadian Crohn’s relapse prevention trial (CCRPT). Gastro-enterology 1991;100:A193.
2. Lofberg R, Danielsson Å, Salde L. Oral budesonide in active ileocecal Crohn’s disease-a pilot trial with a topically acting steroid. Gastroenterology 1991;100:A226.
3. Pallone F, Prantera C, Cottone M, Brunetti G, Miglioli M, and an Italian Study Group. Maintenance treatment of Crohn’s disease with oral 5-ASA (Asacol). Gastroenterology 1991;100:A237.
4. Singleton J, Gitnick G, Hanauer S, et al. Response of Crohn’s disease to oral Pentasa (controlled-release mesa-lamine) as a function of disease location and prior therapy:results of a multicenter study. Gastroenterology 1991;100:A251.
5. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med 1987;316:450-5.
6. Labbe KA, Detsky AS, O’Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987;107:224-33.
7. Anthonisen P, Barany F, Folkenberg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin(r)) in Crohn’s disease. A controlled double-blind study. Scand J Gas-troenterol 1974;9:549-54.
8. Baron JH, Bennet PN, Lennard Jones JE, et al. Sulpha-salazine in asymptomatic Crohn’s disease. A multicentre trial. Gut 1977;18:69-72.
9. Wenkert A, Kristenen M, Eklund AE, et al. The long-term effect of salazosulphapyridine (Salazopyrin(r)) in primarily resected patients with Crohn’s disease. A controlled double-blind trial. Scand J Gastroenterol 1978;13:161-7.
10. Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn’s disease study:results of drug treatment. Gastroenterology 1979;77:847-69.
11. van Hees PAM, van Lier HJJ, van Elteren, PH, et al. Effect of sulphasalazine in patients with active Crohn’s disease:a controlled double-blind study. Gut 1981;22:404-9.
12. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn’s disease study (ECCDS):results of drug treatment. Gastroenterology 1984;86:249-66.
13. Ambrose NS, Allan RN, Keighley MRB, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn’s disease. A prospective randomized study. Dis Colon Rectum 1985;28:81-5.
14. Rasmussen SN, Lauretsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa(r). Scand J Gastroenterol 1987;22:877-83.
15. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn’s disease in relation to radi-cality of operation and sulfasalazine prophylaxis:a multicenter trial. Digestion 1989:224-32.
16. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa(r)) for the treatment of active Crohn’s disease. Digestion 1990;45:88-92.
17. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. Gastroenterology 1976;70:439-44.
18. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980;i:514-5.
19. van Hees PAM, van Elteren, PH, van Lier HJJ, Tongeren JHM. An index of inflammatory activity in patients with Crohn’s disease. Gut 1980;21:279-86.